NASDAQ$OLMA
Olema Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Olema Oncology reported its financial and operating results for the first quarter ended March 31, 2025, highlighting progress in its clinical trials and a strong cash position.
Olema Oncology reported a net loss of $30.4 million for the first quarter of 2025, a slight improvement from the $31.0 million loss in the same period last year, primarily due to higher interest income. The company ended the quarter with $392.7 million in cash, cash equivalents, and marketable securities, indicating a strong financial position to support its ongoing clinical development programs, including the pivotal Phase 3 OPERA-02 and OPERA-01 trials for palazestrant.
- Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib is on track for initiation in 2025.
- Pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy continues to advance with top-line data anticipated in 2026.
- Preclinical data for OP-3136 demonstrated anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models.
- The company maintained a strong financial position, ending the quarter with $392.7 million in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
Olema · Revenue · Quarterly
$0
Forward guidance
Olema Oncology anticipates continued progress in its clinical development programs, with key milestones expected in the coming years, including the initiation of the pivotal Phase 3 OPERA-02 trial and top-line data from the OPERA-01 trial.
Tailwinds
- Initiation of pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer in 2025.
- Anticipated top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer in 2026.
- Presentation of trial-in-progress poster for OPERA-01 at the ASCO Annual Meeting in June.
- Presentation of mature data from the Phase 1b/2 trial of palazestrant in combination with ribociclib at an upcoming medical meeting.
- Continued enrollment in the Phase 1 study for OP-3136.
Headwinds
- No specific negative forward guidance was provided in the report.
- The company's financial performance is subject to risks and uncertainties inherent in clinical development.
- Future results could differ materially from current expectations.
- The company assumes no obligation to update forward-looking statements.
- Success of clinical trials is not guaranteed and depends on various factors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.1%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+7.5%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+17.0%
Q4 2021
Best reaction
-28.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.2% | -7.7% | -29.4% | |
| Q3 2025 | +4.1% | +0.6% | +267.4% | |
| Q2 2025 | +16.0% | +20.6% | +75.1% | |
| Q1 2025 | +2.1% | +9.6% | -11.0% | |
| Q4 2024 | -8.5% | +4.3% | +6.8% | |
| Q3 2024 | -9.7% | -27.9% | -47.2% | |
| Q1 2024 | -12.5% | -18.0% | +16.8% | |
| Q4 2023 | -6.6% | -11.2% | -15.8% | |
| Q3 2023 | -7.6% | -7.4% | -29.2% | |
| Q2 2023 | +15.3% | +14.0% | +24.7% | |
| Q1 2023 | +1.1% | +6.1% | -0.3% | |
| Q4 2022 | +0.0% | +0.3% | -15.4% | |
| Q3 2022 | -7.2% | +5.6% | -22.5% | |
| Q2 2022 | -28.5% | -29.4% | -23.1% | |
| Q1 2022 | -1.3% | -3.1% | +79.4% | |
| Q4 2019 | +17.0% | -2.2% | -5.9% | |
| Q4 2021 | +17.0% | -2.2% | -5.9% | |
| Q3 2021 | +1.1% | -1.9% | -61.9% | |
| Q3 2020 | +1.1% | -1.9% | -61.9% | |
| Q2 2020 | +3.4% | +1.9% | +11.2% | |
| Q2 2021 | +3.4% | +1.9% | +11.2% | |
| Q1 2021 | +11.9% | +14.8% | +35.8% | |
| Q4 2020 | -10.2% | -23.2% | -27.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro